Welcome to the e-CCO Library Archive!

Filter:

Prevalence of anemia in Serbian patients with inflammatory bowel disease

D. Mijac, G. Jankovic, M. Krstic, D. Culafic, I. Rankovic, D. Tomic, S. Djuranovic, Belgrade University, Clinic for Gastroenterology and Hepatology, Clinical Center of Serbia, Belgrade, Serbia

P601. Abnormal liver function tests following use of thiopurines in a large cohort of inflammatory bowel disease patients – do TPMT levels matter?

Authors:

A. Nelson¹, L.C. Harrison¹, B. Matthew², R.A. Cole², K. Ashton¹, S. Sebastian³, ¹Hull & East Yorkshire NHS Trust, United Kingdom, ²Hull & York Medical School, United Kingdom, ³Hull & East Yorkshire NHS Trust, Hull & York Medical School, United Kingdom

P601

Postoperative Crohn's Disease, Recurrence Rate and Risk Factors

Authors:

S.L. Jaspers¹, M. Duijvestein*¹, A.E. van der Meulen - de Jong², G.R. D'Haens¹

¹Academic Medical Center (AMC), Gastroenterology and Hepatology, Amsterdam, Netherlands, ²Leiden University Medical Center (LUMC), Gastroenterology and Hepatology, Leiden, Netherlands

P602.

Prevalence of inflammatory bowel disease in patients with spondyloarthritis and psoriasis. The AQUILES study

Authors:

I. Marín-Jiménez¹, V. García², M. Chaparro³, P. López⁴, I. Moral⁵, P. Zarco⁶, A. Rodríguez de la Serna⁷, F. Vanaclocha⁸, B. Juliá⁹, L. Cea-Calvo⁹, R. García de Vicuña¹⁰, ¹Gregorio Marañón Hospital, Gastroenterology, Madrid, Spain, ²Reina Sofia Hospital, IMIBIC, UCO, Gastroenterology, Córdoba, Spain, ³La Princesa Hospital, IP and CIBERehd, Gastroenterology, Madrid, Spain, ⁴Alcorcón Foundation Hospital, Gastroenterology, Madrid, Spain, ⁵Príncipe de Asturias Hospital, Gastroenterology, Madrid, Spain, ⁶Alcorcón Foundation Hospital, Rheumatology, Madrid, Spain, ⁷Sant Pau Hospital, Rheumatology, Barcelona, Spain, ⁸12 de Octubre Hospital, Dermatology, Madrid, Spain, ⁹Merck Sharp & Dohme de España, Medical Affairs, Madrid, Spain, ¹⁰La Princesa Hospital, IISP, Rheumatology, Madrid, Spain

P602. Azathioprine in the maintainance of steroid-free remission in inflammatory bowel disease patients: one-year efficacy and safety

Authors:

C. Cassieri¹, R. Pica¹, E.V. Avallone¹, M. Zippi¹, C. Corrado¹, P. Vernia¹, P. Paoluzi¹, E.S. Corazziari¹, ¹Sapienza University, Internal Medicine and Medical Specialties, “Gastroenterology Unit”, Rome, Italy

P602

Secondary healthcare use following major abdominal surgery employing an acellular reconstructive tissue matrix

Authors:

S. Das Mohapatra¹, J. O'Hara*^{2, 3}, C. Camp², D. Hughes^{2, 3}, A.C.J. Windsor¹

¹University College London Hospital, Colorectal Service, London, United Kingdom, ²Healthcare Decisions, Ltd., Daresbury, United Kingdom, ³University of Chester, Faculty of Health and Social Care, Chester, United Kingdom

P603.

Prevalence and characteristics of extra-intestinal manifestations in a Greek population of inflammatory bowel disease patients followed-up in tertiary centers

Authors:

K. Karmiris¹, A. Avgerinos², A. Tavernaraki¹, G.I. Mantzaris³, T. Koukouratos³, K. Oikonomou⁴, A. Kostas⁵, N. Viazis³, A. Kapsoritakis⁴, G. Bamias⁵, A. Theodoropoulou¹, D.G. Karamanolis³, I.E. Koutroubakis², ¹Venizeleio General Hospital, Gastroenterology, Heraklion, Crete, Greece, ²University Hospital, Gastroenterology, Heraklion, Crete, Greece, ³Evaggelismos Hospital, Gastroenterology, Athens, Greece, ⁴University Hospital, Gastroenterology, Larissa, Greece, ⁵Laiko Hospital, Gastroenterology, Athens, Greece

P603. Anti-TNF treatment is effective in inducing remission and restoring nutritional status in pediatric inflammatory bowel disease

Authors:

J. Martín de Carpi¹, M. Navalón¹, R. García-Romero¹, V. Vila¹, S. Pinillos¹, V. Varea¹, ¹Hospital Sant Joan de Déu, Paediatric Gastroenterology, Barcelona, Spain

P603

Efficacy of the new infliximab biomarker CT-P13 induction therapy on mucosal healing in ulcerative colitis patients

Authors:

T. Molnar*, K. Farkas, M. Rutka, A. Bálint, F. Nagy, R. Bor, Á. Milassin, Z. Szepes

University of Szeged, 1st Department of Medicine, Szeged, Hungary

P604.

Prevalence and characteristics of dermatologic manifestations in a Greek population of inflammatory bowel disease patients followed-up in tertiary centers

Authors:

P604. Adalimumab for the treatment of post-operative recurrence of Crohn's disease. A single centre experience

Authors:

C. Praticò¹, F. Rizzello¹, A. Calafiore¹, C. Calabrese¹, G. Poggioli², S. Laureti², M. Campieri¹, P. Gionchetti¹, ¹Bologna, Clinical Medicine, Bologna, Italy, ²Bologna, General Surgery, Bologna, Italy

P604

Stigma in Inflammatory Bowel Disease

Authors:

L. Dibley*

, C. Norton,¹ E. Mason-Whitehead²

¹King's College London, Florence Nightingale Faculty of Nursing & Midwifery, London, United Kingdom,

²University of Chester, United Kingdom

P605.

Presentation and progression of childhood-onset inflammatory bowel disease in northern Stockholm County

Authors:

P. Malmborg¹, L. Grahnquist¹, M. Ideström^1,2, J. Björk³, R. Befrits³, J. Lindholm⁴, S. Montgomery^3,5, H. Hildebrand¹, ¹Karolinska Institutet, Department of Women's and Children's Health, Stockholm, Sweden, ²20 de Noviembre National Medical Center, ISSSTE, Gastroenterology, Mexico City, Mexico, ³Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Department of Oncology-Pathology, Stockholm, Sweden, ⁵Örebro University Hospital & Örebro University, Clinical Epidemiology and Biostatistics, Örebro, Sweden

P605. Adalimumab (ADA) and infliximab (IFX) therapy during pregnancy in IBD: a prospective assessment of outcome, safety and cord blood levels

Authors:

S. Traussnigg¹, A. Eser¹, C. Primas¹, P. Papay¹, C. Gratzer¹, S. Angelberger¹, A. Mikulits¹, W. Reinisch¹, M. Trauner¹, H. Vogelsang¹, G. Novacek¹, C. Dejaco¹, ¹Medical University Vienna, Internal Medicine III Gastroenterology and Hepatology, Vienna, Austria

P605

Serum hepcidin and its relation to anaemia in inflammatory bowel disease

Authors:

R. Dudkowiak*¹, K. Neubauer¹, P. Petryszyn², E. Poniewierka¹

¹Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland, ²Wroclaw Medical University, Clinical Pharmacology, Wroclaw, Poland

P606.

Phenotypic characteristics and use of therapeutic resources in elderly-onset inflammatory bowel disease: A multicentre, case–control study

Authors:

M. Mañosa¹, M. Calafat¹, R. de Francisco², C. Garcia³, M.J. Casanova⁴, P. Huelin⁵, Y. Zabana⁶, M. Calvo⁷, M. Mínguez⁸, A. Ruiz⁹, G. Bastida¹⁰, J. Hinojosa¹¹, L. Márquez¹², M. Barreiro-de-Acosta¹³, X. Calvet¹⁴, D. Monfort¹⁵, R. Gómez¹⁶, E. Rodríguez¹⁷, J.M. Huguet¹⁸, M. Rojas¹⁹, D. Hervas²⁰, R. Atienza²¹, D. Busquets²², E. Zapata²³, C. Dueñas²⁴, M. Charro²⁵, F.J. Martínez-Cerezo²⁶, R. Plaza²⁷, J.M. Vázquez²⁸, J.P. Gisbert⁴, E. Cabré¹, E. Domènech¹, ¹Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, ²Hospital Central de Asturias, Department Gastroenterology, Oviedo, Spain, ³Hospital Reina Sofía, Gastroenterology, Córdoba, Spain, ⁴Hospital Universitario de La Princesa, IP and CIBERehd, Gastroenterology Unit, Madrid, Spain, ⁵Hospital Santa Creu i Sant Pau, Gastroenterology Unit, Barcelona, Spain, ⁶Hospital Universitario Mutua de Terrassa and CIBERehd, Gastroenterology Unit, Terrasa, Spain, ⁷Hospital Puerta de Hierro, Gastroenterology Unit, Madrid, Spain, ⁸Hospital Clínic de Valencia, Gastroenterology, Valencia, Spain, ⁹Hospital de Bellvitge. Idibell, Gastroenterology, Hospitalet de Llobregat, Spain, ¹⁰Hospital La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain, ¹¹Hospital de Manises, IBD unit, Manises, Spain, ¹²IMIM. Hospital del Mar Medical Research Institute. Pompeu Fabra University, Gastroenterology Unit, Barcelona, Spain, ¹³Hospital Universitario de Santiago, Gastroenterology, Santiago de Compostela, Spain, ¹⁴Hospital De Sabadell, Institut Universitari Parc Taulí, Digestive, Sabadell, Spain, ¹⁵Consorci Sanitari Terrassa, Gastroenterology, Terrassa, Spain, ¹⁶Hospital Virgen de las Nieves, Gastroenterology, Granada, Spain, ¹⁷Hospital Nuestra Sra de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain, ¹⁸Hospital General Universitario, Digestivo, Valencia, Spain, ¹⁹Hospital de Valme, Unidad de Gestión Clínica de Enfermedades Digestivas, Sevilla, Spain, ²⁰Hospital de Manzanares, Gastroenterology, Ciudad Real, Spain, ²¹Hospital Río Hortega, Gastroenterology, Valladolid, Spain, ²²Hospital universitari de Girona, Dr Trueta, Gastroenterology, Girona, Spain, ²³Hospital de Mendaro, Gastroenterology, Mendaro, Spain, ²⁴Hospital de Cáceres, Gastroenterology, Cáceres, Spain, ²⁵Hospital Royo Vilanova, Gastroenterology, Valladolid, Spain, ²⁶Hospital Sant Joan, Gastroenterology, Reus, Spain, ²⁷Hospital Infanta Leonor, Gastroenterology, Madrid, Spain, ²⁸Hospital Juan Ramón Jiménez, Gastroenterology, Huelva, Spain

P606. Once-daily versus three-times-daily oral budesonide in active Crohn's disease: a double-blind, double-dummy, randomized trial

Authors:

A. Dignass¹, V. Grinevich², M. Zakharash³, A. Goldis⁴, L. Jonaitis⁵, L. Gabalec⁶, G. Vasileva⁷, I. Rácz⁸, B. Pekárková⁹, J. Derova¹⁰, R. Greinwald¹¹, R. Mueller¹¹, ¹Agaplesion Markus-Krankenhaus, Dept. of Medicine I, Frankfurt, Germany, ²I.M. Sechenov First Moscow Medical State University, Dept. of Conservative Coloproctology, Moscow, Russian Federation, ³O.O. Bogomolets National Medical University, Chair of surgery No. 1, City Clinical hospital No. 18, Dept. of Proctology, Kiev, Ukraine, ⁴Algomed Policlinic, Timisoara, Romania, ⁵Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Dept. of Endoscopy, Kaunas, Lithuania, ⁶Orlickoústecká nemocnice, a.s., Ústí nad Orlicí, Czech Republic, ⁷MBAL Rousse, IIIrd Therapeutic Ward – Gastroenterology 2, Rousse, Bulgaria, ⁸Petz Aladár Megyei Kórház, I. Belgyógyászat, Györ, Hungary, ⁹GEA s.r.o, Gastroenterology Department, Trnava, Slovakia, ¹⁰Latvian Maritime Medical Centre, Riga, Latvia, ¹¹Dr Falk Pharma GmbH, Dept. of Clinical Research & Development, Freiburg, Germany

P606

Is it necessary to include disease extent in endoscopic scoring in ulcerative colitis?

Authors:

A. Balint*, K. Farkas, Z. Szepes, F. Nagy, R. Bor, A. Milassin, M. Rutka, T. Molnar

University of Szeged, First Department of Medicine, Szeged, Hungary

P607.

Prescription of enteral nutrition in paediatric Crohn's disease in Spain; the present survey

Authors:

V.M. Navas-Lopez¹, J. Martín-de-Carpi², Ó. Segarra-Canton³, J.I. Garcia-Burriel⁴, J.J. Díaz-Martín⁵, A. Rodríguez-Martínez⁶, E. Medina-Benitez⁷, M. Juste-Ruiz⁸, ¹Hospital Materno Infantil, Pediatric Gastroenterology and Nutrition Unit, Malaga, Spain, ²Hospital Sant Joan de Deu, Pediatric Gastroenterology and Nutrition Unit, Barcelona, Spain, ³Hospital Vall de Hebrón, Paediatric Gastroenterology and Nutrition Unit, Barcelona, Spain, ⁴Complexo Hospitalario Universitario de Vigo, Paediatric Gastroenterology and Nutrition Unit, Vigo, Spain, ⁵Hospital Universitario Central de Asturias., Paediatric Gastroenterology and Nutrition Unit, Oviedo, Spain, ⁶Hospital Universitario Virgen del Rocío Sevilla, Paediatric Gastroenterology and Nutrition Unit, Sevilla, Spain, ⁷Hospital Doce de Octubre, Paediatric Gastroenterology and Nutrition Unit, Madrid, Spain, ⁸Hospital Clínico Universitario San Juan de Alicante, Paediatric Gastroenterology and Nutrition Unit, San Juan de Alicante, Spain

P607. Complications to surgical treatment for Crohn's disease: a 10 year observational study from St. Olavs Hospital, 2000–2009

Authors:

S. Breder¹, B.H. Endreseth², A. Rydning², ¹Innlandet Hospital Gjovik, Department of Surgery, Gjovik, Norway, ²St. Olavs Hospital, Trondheim University Hospital, Department of Gastrointestinal Surgery, Trondheim, Norway


All Abstracts Documents Images Podcasts Webcasts
search by: